Harms M, Philippe I, Radeff B, Masouyé I, Geiger J M, Saurat J H
Acta Derm Venereol. 1986;66(2):149-54.
Thirty patients have been treated with either etretin, the main derivative of etretinate, or arotinoid Ro 13-6298, a polyaromatic retinoid, or isotretinoin. Sebum production was measured before and during the treatments. While no change was observed in the patients treated with etretin, a reduction of 33% of the sebum excretion rate was observed for those treated with arotinoid Ro 13-6298 but only after long treatment periods of 20 to 30 weeks. The sebum excretion rate decreased by 92% in the patients treated with isotretinoin. Four patients suffering from severe nodulocystic acne were treated with arotinoid Ro 13-6298 for 2-5 months without improvement. Substantial improvement, however, resulted after a subsequent treatment with isotretinoin; sebum production decreased markedly as well. This study suggests that neither etretin nor arotinoid Ro 13-6298 will replace isotretinoin in the treatment of severe nodulocystic acne.
30名患者接受了以下治疗：阿维A（维甲酸的主要衍生物）、芳香维甲酸Ro 13 - 6298（一种多芳香族维甲酸）或异维A酸。在治疗前和治疗期间测量了皮脂分泌情况。接受阿维A治疗的患者未观察到变化，而接受芳香维甲酸Ro 13 - 6298治疗的患者，仅在20至30周的长期治疗后，皮脂排泄率降低了33%。接受异维A酸治疗的患者皮脂排泄率下降了92%。4名重度结节囊肿性痤疮患者接受芳香维甲酸Ro 13 - 6298治疗2至5个月，未见改善。然而，随后用异维A酸治疗后有显著改善；皮脂分泌也明显减少。这项研究表明，在重度结节囊肿性痤疮的治疗中，阿维A和芳香维甲酸Ro 13 - 6298都不会取代异维A酸。
